MiniMed Debuts on Nasdaq With $5.35 Billion Valuation

The diabetes-focused business of Medtronic plc, MiniMed, saw its shares fall during its Nasdaq debut on Friday as market volatility impacted investor appetite. The company's stock opened at $19.05, down 4.8% from its $20.00 offer price, giving the firm a valuation of $5.35 billion. The initial public offering raised $560 million through the sale of 28 million shares, though the final price was well below the initial target range of $25 to $28. Market conditions in the United States have remained challenging for new listings due to uncertainty surrounding geopolitical conflicts and economic data. On the day of the listing, the CBOE Volatility Index reached its highest level in four months following a disappointing jobs report. > "MiniMed going ahead with its IPO amid high market volatility shows that the U.S. IPO market is still open, but that it has become a price-sensitive buyers market," said IPOX Research Associate Lukas Muehlbauer. MiniMed was established in 1983 and was acquired by Medtronic nearly a quarter-century ago. The company produces a variety of diabetes management tools, including insulin pumps and glucose monitoring sensors. Despite previous regulatory challenges and cybersecurity concerns, the business has recently seen a resurgence in growth. > "I dont think about the business as being a turnaround anymore. Were really at the point of acceleration," MiniMed CEO Que Dallara told Reuters. Looking ahead, the company plans to expand its product portfolio with the spring launch of MiniMed Go, a smart multiple daily injection system. The firm had originally sought a valuation exceeding $7 billion, but analysts noted that growth prospects were heavily scrutinized by investors during the pricing process.